Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC): Final appraisal document
In DRAFT guidance, NICE recommends pembrolizumab as an option for untreated metastatic or unresectable recurrent HNSCC in adults whose tumours express PD-L1 with a CPS≥1, only if used as monotherapy and stopped after 2 years or earlier if disease progresses.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The draft guidance is additionally contingent upon the company providing pembrolizumab according to the commercial arrangement.
The Institute of Cancer Research has called on NICE to make pembrolizumab available in combination with chemotherapy via the Cancer Drugs Fund for two years, to allow for additional data collection, and to help identify new biomarkers to predict patients’ response.